Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study

BACKGROUND: This double-blind, parallel-group, multicenter, phase-3 study was designed to test the noninferiority of paliperidone palmitate 3-month formulation (PP3M) to the currently marketed 1-month formulation (PP1M) in patients (age 18–70 years) with schizophrenia, previously stabilized on PP1M....

Descripción completa

Detalles Bibliográficos
Autores principales: Savitz, Adam J., Xu, Haiyan, Gopal, Srihari, Nuamah, Isaac, Ravenstijn, Paulien, Janik, Adam, Schotte, Alain, Hough, David, Fleischhacker, Wolfgang W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966278/
https://www.ncbi.nlm.nih.gov/pubmed/26902950
http://dx.doi.org/10.1093/ijnp/pyw018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966278/
https://www.ncbi.nlm.nih.gov/pubmed/26902950
http://dx.doi.org/10.1093/ijnp/pyw018

Ejemplares similares